ReviewClinical microbiology reviews1997
Antifungal prophylaxis during neutropenia and immunodeficiency.
Review in Clinical microbiology reviews, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Interventions for preventing oral mucositis for patients with cancer receiving treatment.The Cochrane database of systematic reviews · 2011Pooled it
- Interventions for treating oral mucositis for patients with cancer receiving treatment.The Cochrane database of systematic reviews · 2010Pooled it
- Myricetin Disturbs the Cell Wall Integrity and Increases the Membrane Permeability ofJournal of microbiology and biotechnology · 2022Article
- Rapid identification of fungi from respiratory samples by Bruker Biotyper matrix-assisted laser desorption/ionisation time-of-flight using ID-FUNGI plates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Control of Mucosal Candidiasis in the Zebrafish Swim Bladder Depends on Neutrophils That Block Filament Invasion and Drive Extracellular-Trap Production.Infection and immunity · 2017Article
- IL-1 Coordinates the Neutrophil Response to C. albicans in the Oral Mucosa.PLoS pathogens · 2016Article
- Autophagy enhances NFκB activity in specific tissue macrophages by sequestering A20 to boost antifungal immunity.Nature communications · 2015Article
- Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.Bone marrow transplantation · 2004Review
- Posttransplantation disseminated coccidioidomycosis acquired from donor lungs.Journal of clinical microbiology · 2004Article
- Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species.Antimicrobial agents and chemotherapy · 2003Article
- Transcription profiling of Candida albicans cells undergoing the yeast-to-hyphal transition.Molecular biology of the cell · 2002Article
- Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.Antimicrobial agents and chemotherapy · 2002Article
- Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.Antimicrobial agents and chemotherapy · 2001Article
- Current management of fungal infections.Drugs · 2001Review
- Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment.Drugs & aging · 2000Review
- Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis.Antimicrobial agents and chemotherapy · 2000Article
- Emerging Issues in Nosocomial Fungal Infections.Current infectious disease reports · 1999Article
- Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents.Antimicrobial agents and chemotherapy · 1999Article
- Current and emerging azole antifungal agents.Clinical microbiology reviews · 1999Review
- Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation.Journal of clinical microbiology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections represent a major source of morbidity and mortality in patients with almost all types of immunodeficiencies. These infections may be nosocomial (aspergillosis) or community acquired (cryptococcosis), or both (candidiasis). Endemic mycoses such as histoplasmosis, coccidioidomycosis, and penicilliosis may infect many immunocompromised hosts in some geographic areas and thereby create major public health problems. With the wide availability of oral azoles, antifungal prophylactic strategies have been extensively developed. However, only a few well-designed studies involving strict criteria have been performed, mostly in patients with hematological malignancies or AIDS. In these situations, the best dose and duration of administration of the antifungal drug often remain to be determined. In high-risk neutropenic or bone marrow transplant patients, fluconazole is effective for the prevention of superficial and/or systemic candidal infections but is not always able to prolong overall survival and potentially selects less susceptible or resistant Candida spp. Primary prophylaxis against aspergillosis remains investigative. At present, no standard general recommendation for primary antifungal prophylaxis can be proposed for AIDS patients or transplant recipients. However, for persistently immunocompromised patients who previously experienced a noncandidal systemic fungal infection, prolonged suppressive antifungal therapy is often indicated to prevent a relapse. Better strategies for controlling immune deficiencies should also help to avoid some potentially life-threatening deep mycoses. When prescribing antifungal prophylaxis, physicians should be aware of the potential emergence of resistant strains, drug-drug interactions, and the cost. Well-designed, randomized, multicenter clinical trials in high-risk immunocompromised hosts are urgently needed to better define how to prevent severe invasive mycoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.